Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine

British Journal of Pharmacology

Volumn 136, Issue 5, 2002, Pages 717-729

  Paul, Ashok A ^a   Witchel, Harry J ^a   Hancox, Jules C ^a  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

Author keywords

Antiarrhythmic; Class Ia; Class Ib; Class Ic; Flecainide; HERG; QT interval; QT prolongation; Quinidine

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; LIDOCAINE; POTASSIUM CHANNEL; PROPAFENONE; QUINIDINE; CATION TRANSPORT PROTEIN; DNA BINDING PROTEIN; ERG PROTEIN, HUMAN; ERG1 POTASSIUM CHANNEL; KCNH2 PROTEIN, HUMAN; KCNH6 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG; TRANSACTIVATOR PROTEIN; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; DRUG POTENCY; ELECTRIC POTENTIAL; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN ETHER A GO GO RELATED GENE; IC 50; ION CURRENT; MONITORING; PRIORITY JOURNAL; TEMPERATURE; TIME; VOLTAGE CLAMP; COMPARATIVE STUDY; DOSE RESPONSE; NERVE CELL INHIBITION; PHYSIOLOGY;

CATION TRANSPORT PROTEINS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FLECAINIDE; HUMANS; LIDOCAINE; NEURAL INHIBITION; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROPAFENONE; QUINIDINE; TRANS-ACTIVATORS;

EID: 0035987783     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704784     Document Type: Article

References (66)

1. Ks cardiac potassium current
2. Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry
3. Kinetics of onset of rate-dependent effects of class 1 antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification
4. Differential effects on action potential duration of class IA, B, and C antiarrhythmic drugs: Modulation by stimulation rate and extracellular K + concentration
5. + channels and control of ventricular repolarisation in the heart
6. Two delayed rectifiers in guinea pig ventricular myocytes distinguished by tail current kinetics
7. Characterization of a new oral antiarrhythmic drug, flecainide (R-818)
8. A molecular basis for cardiac arrhythmia: HERG mutations cause Long QT syndrome
9. Propafenone preferentially blocks the rapidly activating component of delayed rectifier K current in guinea pig ventricular myocytes
10. Potassium channel blocking properties of propafenone in rabbit atrial myocytes
11. Flecainide
12. Effects of propafenone on calcium currents in single ventricular myocytes of guinea-pig
13. K, by flecainide and E-4031 in cat ventricular myocytes
14. Differential block of cardiac delayed rectifier current by class Ic antiarrhythmics: Evidence for open channel block and unblock
15. Steady-state quinidine concentration: Role in prophylactic therapy following acute myocardial infarction
16. Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential
17. Inhibition of L-type calcium current by propafenone in single myocytes isolated from the rabbit atrioventricular node
18. Ks in guinea-pig isolated ventricular myocytes
19. Propafenone-induced Torsades de Pointes: Cross-reactivity with quinidine
20. + channels by vesnarinone
21. An amino acid residue whose change by mutation affects drug binding to the HERG channel
22. + channels
23. Molecular determinant of high affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites
24. A method for making rapid changes of superfusate whilst maintaining temperature at 37°C
25. The value of quinidine in cases of auricular fibrillation and methods of studying the clinical reaction
26. Stereoselective effects of disopyramide enantiomers in humans
27. Flecainide-induced QT prolongation and ventricular tachycardia
28. Comparison of intravenous mexiletine and lidocaine for the treatment of ventricular arrhythmias
29. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel
30. A structural basis for drug-induced long QT syndrome
31. Trapping of a methanesufonanlide by closure of the HERG potassium channel activation gate
32. An investigation of the role played by the E-4031-sensitive (rapid delayed rectifier) potassium current in isolated rabbit atrioventricular nodal and ventricular myocytes
33. Characteristics of a transient outward current (sensitive to 4-aminopyridine) in Ca-tolerant myocytes isolated from the rabbit atrioventricular node
34. Evolution, mechanisms and classification of antiarrhythmic drugs: Focus on class III actions
35. Inhibition of HERG potassium channel current by the Class 1a antiarrhythmic agent disopyramide
36. Modulation of HERG potassium channels by extracellular magnesium and quinidine
37. Modulation of flecainide's cardiac sodium channel blocking actions by extracellular sodium: A possible cellular mechanism for the action of sodium salts in flecainide cardiotoxicity
38. Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction
39. Rate dependency of delayed rectifier currents during the guinea-pig ventricular action potential
40. Spectrum of HERG K channel dysfunction in an inherited cardiac arrhythmia
41. Ks potassium channel
42. Kr potassium channel
43. + current
44. + current is composed of two currents in guinea pig atrial cells
45. Sotalol, propafenone and flecainide: Compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy
46. Ca in single frog cardiac cells by quinidine, flecainide, ethmozin and ethazin
47. The inward rectification mechanism of the HERG cardiac potassium channel
48. High affinity open channel block by dofetilide of HERG expressed in a human cell line
49. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel
50. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline
51. HERG, an inward rectifier in the voltage-gated potassium channel family
52. + channels: Friend and foe
53. Effect of disopyramide on potassium currents in rabbit ventricular myocytes
54. Long QT syndromes and torsade de pointes
55. Comparative effects of azimilide and ambisilide on the human ether-a-go-go related gene (HERG) potassium channel
56. Comparison of the effects of class-I antiarrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K current of guinea-pig ventricular myocytes
57. Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue
58. QT prolongation and induction of torsade de pointe by flecainide. Apropos of a case
59. Congenital and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium channel
60. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents
61. Flecainide inhibits the transient outward current in atrial myocytes isolated from the rabbit heart
62. Kr. Implications for torsade de pointes and reverse use-dependence
63. o dependence of the rapid component of the delayed rectifier K current in cardiac cells
64. Kr: Model systems and relevance to human arrhythmias
65. Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current
66. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature